Reimbursement Advantage Hailie provides real-time adherence data and auditable reimbursement reports, with RPM payments already in place and a funded technology upgrade to unlock US reimbursement—creating an immediate sales angle with payers and providers seeking cost savings in asthma and COPD management.

US Market Access The company has the widest US inhaler market coverage and a path to reimbursement through a funded upgrade, enabling scalable sales to health systems, insurers, and patient programs in the United States.

Clinical ROI Extensive clinical evidence (over 85 studies with ~13,000 patients) supports improved adherence and outcomes, providing a strong basis for ROI-focused conversations and value-based contracts with payers and providers.

Platform & Integration A cloud-based data platform and patented sensors can be integrated into clinical workflows and EMRs, backed by ISO 13485 and ongoing tech upgrades to support enterprise deployments.

Global Scale & Partnerships 170,000 devices deployed across 30 countries and active strategic partnerships create a foundation for multi-market expansion, cross-sell to payers/providers, and collaboration with pharma on adherence programs.